Abstract
INTRODUCTION
Aortic valve replacement (AVR) using the Ross procedure has shown excellent results, provided the operation is performed in a centre with the necessary expertise [1] [2] [3] . Survival, in these centres, has been shown to be equivalent to an age-and sexmatched population [2] . Patients do not require anticoagulation, and haemodynamic results are excellent [4] . Despite being a 2-valve operation, it is associated with a relatively low rate of reoperation in experienced hands [1, 5] . However, results are not as good in the younger patient group presenting with pure aortic regurgitation (AR), compared to that achieved in those with aortic stenosis or mixed disease [6, 7] . Most of these patients have a bicuspid aortic valve (BAV) as the pathological basis of their valvular regurgitation. Perhaps in view of the inferior results in this group, all guidelines including the Society of Thoracic Surgeons (STS) and American Heart Association (AHA)/American College of Cardiology (ACC) guidelines currently recommend a mechanical valve as the optimal choice in patients younger than 60 years of age, unless there are contraindications for anticoagulation with warfarin [8, 9] . Our approach to these patients has been to offer a Ross procedure when anticoagulation is either contraindicated or deemed to be unacceptable by the patient. The current guidelines allocate the Ross procedure a Class III recommendation, stating that it should not be performed in patients with BAV and AR.
Meanwhile, the latest European Association for CardioThoracic Surgery (EACTS) guidelines recommend that repair of the regurgitant valves is considered when the valve morphology permits, due to its association with lower valve-related event rates and an improved quality of life [10] . Our unit has commenced a programme of aortic valve repair in patients with BAV and AR, and has achieved good results in selected patients. However, we believe that the Ross procedure is a viable surgical option that deserves consideration. As such, we decided to review our 25-year experience with the Ross procedure in this patient cohort.
PATIENTS AND METHODS
Ethical approval for this study was obtained from the Royal Melbourne Hospital Human Research Ethics Committee for the review of outcomes of all patients undergoing the Ross procedure within the unit (HREC QA20130104). Four-hundred and twenty consecutive patients underwent the Ross procedure between 1992 and January 2017. Of these, 129 patients presented with BAV and pure AR, comprising the study cohort. Pure AR was defined as the presence of AR without any aortic stenosis.
The baseline demographics and preoperative and operative factors were collated. Preoperative aortic dimensions were mostly derived from transthoracic or transoesophageal echocardiography. In the setting of aortic dilatation, further evaluation was performed with computed tomography, and larger dimensions were reported. Follow-up data of the 129 patients were reviewed. All patients received yearly clinical review and biannual transthoracic echocardiogram during follow-up. All deaths during the follow-up period were ascertained. Patients lost to follow-up were subjected to a search in the Australian National Death Registry to confirm survival status. The primary end point of the review was all-cause mortality. Secondary end points included surgical reintervention of the aortic valve and recurrence of significant AR, defined as moderate or severe AR on follow-up transthoracic echocardiogram.
Patient selection criteria varied through the study period. Between 1992 and 1999, all patients with significant AR were offered the surgical option of a Ross procedure, regardless of their aortic root size. In the following decade between 2000 and 2009, aortic root enlargement was identified to be an important preoperative predictor of poor surgical outcomes [7] . As such, the Ross procedure was only offered to patients without significant aortic root enlargement, defined as sinotubular junction size <34 mm. From 2009 to present, a modification of the Ross procedure was introduced, where patients with larger aortic roots underwent surgery with the pulmonary autograft valve inserted within a Valsalva Dacron graft (Gelweave Valsalva; Sulzer Vascutek, Renfrewshire, Scotland), allowing for the Ross procedure to be offered even to patients with aortic root enlargement [1] . Those without significant aortic root dilation underwent the Ross procedure using the standard autologous external support inclusion technique (Fig. 1) . This involved the implantation of their pulmonary autograft within their aortic root, which acted as an external scaffold preventing subsequent aortic root dilatation [7] .
The strategy for aortic root preparation has been previously described, and aims to achieve an ideal aortic annulus size of 22-24 mm diameter in women and 24-26 mm in men [7] . Appropriate aortic root reduction in those with enlargement was performed based on pre-operative aortic annulus and sinotubular junction dimensions. Minor reduction (1-3 mm diameter reduction) was most commonly achieved with the insertion of a partial circumferential external polyester band. Greater degree of reduction (> _4 mm) required additional strategies including wedge or quadrangular resection of the non-coronary sinus tissue and plication sutures. The enlarged sinotubular junction and ascending aorta were managed with a variety of measures, including sinotubular ring, tailoring aortoplasty (if ascending aorta < _45 mm) and Dacron graft replacement of the ascending aorta (if ascending aorta diameter >45 mm). We did not perform prophylactic replacement or repair of the non-dilated aortic root and/or ascending aorta.
Pulmonary valve replacement (PVR) was routinely performed with a cryopreserved pulmonary valve allograft. Meticulous myocardial protection was achieved throughout surgery using intermittent antegrade and retrograde tepid blood cardioplegia every 15 min. A transthoracic echocardiogram was performed biannually to monitor valve function, ventricular size and function as well as surveillance of the aortic root and ascending aorta. A liberal reoperation policy was adopted, where reoperation was recommended if patients developed moderate or severe AR post-Ross surgery, and if their left ventricular end-diastolic diameter (LVEDD) exceeded 6 cm on follow-up imaging. Pulmonary allograft function was also monitored with serial echocardiography. Indications for reoperation on the pulmonary valve were development of pulmonary allograft stenosis (mean pulmonary valve gradient >35 mmHg); and moderate or greater pulmonary regurgitation with symptoms or without symptoms but with significant right ventricular dilation. Follow-up was deemed to be complete if patients underwent clinical review or echocardiography after January 2015 or within the year before death.
Statistical analysis
Patient baseline characteristics were summarized using mean (standard deviation) or median [interquartile range] for continuous variables and percentages for categorical variables. Survival analysis was performed using the Kaplan-Meier method. A Cox proportional hazard model was used to examine the variables, from which the hazard ratios of the chosen end point and their 95% confidence intervals were generated. The proportional hazards assumption was assessed based on the method of Harrell-Lee via diagnostic plots. Univariable analysis was performed on all variables to determine the hazard ratio for redo AVR or recurrent AR.
RESULTS
There were 129 patients with BAV and pure AR who underwent the Ross procedure during the study period. Patient characteristics are described in Table 1 . The mean age at the time of Ross procedure was 34.7 ± 10.6 years (range 16-64 years). Sixty-four (50%) patients had symptoms of effort dyspnoea at the time of surgery [preoperative New York Heart Association (NYHA) class in Table 1 ]. Of the group, 118 (91%) patients had normal or mildly impaired left ventricular function preoperatively. Most patients had significant left ventricular dilation, with a mean LVEDD of 6.4 ± 0.6 cm. Mean aortic annulus and sinotubular junction diameters were 30.8 ± 3.3 mm and 28.9 ± 4.3 mm, respectively.
Eleven (9%) patients had the Ross procedure with external reinforcement using a Valsalva graft, and the remaining patients underwent the Ross procedure with the autologous support technique. All except 6 of the remaining patients needed adjunctive aortic root augmentation or reduction, most commonly with a Dacron partial annuloplasty ring (n = 93; 72%), and 74 (57%) patients needed ascending aortic reduction or replacement. All adjunctive aortic procedures are summarized in Table 2 . Mean aortic annulus diameter post-augmentation was 25.0 ± 1.5 mm. The mean cross-clamp and cardiopulmonary bypass times were 178.3 ± 18.3 min and 203.7 ± 22.5 min, respectively.
Three patients had to return to theatre for bleeding, 2 patients had low cardiac output requiring insertion of intra-aortic balloon pump and there were 2 patients with new acute renal failure. All early postoperative complications are summarized in Table 3 . The mean duration of postoperative invasive ventilation was 9.7 ± 3.9 h, and the mean duration of intensive care stay was 1.4 ± 0.6 days. Patients were discharged after a mean of 7.3 ± 1.7 days post-surgery. One perioperative death was reported due to myocardial infarction, with an early operative survival of 99%. The remaining 128 patients were followed up over a mean duration of 9.6 ± 6.8 years with 98% completion rate. These patients made up the cohort for subsequent analysis.
Three late deaths were reported at 4, 11 and 12 years postsurgery due to non-cardiac causes, specifically cancer (2 patients) and suicide (1 patient). Late survival at 10 and 20 years was 99% [95% confidence interval (CI) 94-100] and 95% (95% CI 85-99), respectively (Fig. 2) . Eleven (9%) patients required reoperation for AVR at a median of 5.3 years (interquartile range 3.4-7.8) after the Ross procedure. All 11 patients had mechanical aortic valve implantations, and 1 of the 11 patients required concurrent ascending aortic repair with a pericardial patch. Of these, 9 (7%) patients underwent redo surgery for recurrent AR. The remaining 2 patients had infective endocarditis, of which 1 patient needed replacement of both aortic and pulmonary valves at 7 years postsurgery. An additional 3 patients had reoperation for PVR. Indications for redo PVR were pulmonary valve stenosis (2 patients) and pulmonary regurgitation (1 patient). Of the 4 pulmonary valve re-replacements, 3 utilized a porcine valve (Medtronic Freestyle valve) and 1 a pulmonary allograft. Freedom from reoperation for PVR at 5, 10, 15 and 20 years was 98% (95% CI 93-99), 97% (95% CI 89-99), 95% (95% CI 86-98) and 95% (95% CI 86-98), respectively. No mortality was reported in any of the redo operations, both aortic and pulmonary.
Freedom from reoperation for AVR at 5, 10, 15 and 20 years was 95% (95% CI 88-98), 89% (95% CI 81-94), 85% (95% CI 74-92) and 85% (95% CI 74-92). There was 1 additional patient (Fig. 2) . Univariable analysis identified preoperative sinotubular junction diameter [hazard ratio (HR) 1.15, 95% CI 1.03-1.30; P = 0.02] as a continuous variable to be a significant predictor of the recurrence of significant AR or redo AVR. In addition, having a preoperative sinotubular junction diameter > _32 mm was strongly predictive of this end point (HR 4.22, 95% CI 1.23-14.4; P = 0.02). Having a longer cross-clamp time (HR 1.03, 95% CI 1.00-1.06; P = 0.05) and cardiopulmonary bypass time (HR 1.02, 95% CI 1.00-1.05; P = 0.05) were also significant predictors of the recurrence of significant AR or redo AVR (Table 4) . Patients who had redo AVR or significant AR had larger preoperative aortic annulus (32.1 ± 2.5 vs 30.7 ± 3.3; P = 0.15) and sinotubular diameters (31.1 ± 5.2 vs 28.8 ± 4.2; P = 0.10), although this was not statistically significant (Table 5) .
At the last follow-up, all patients were in NYHA Class I and had normal left ventricular systolic function on echocardiography (Table 6) . A significant reduction in mean LVEDD was observed on follow-up echocardiogram (postoperative vs preoperative LVEDD: 5.2 ± 0.5 cm vs 6.4 ± 0.6 cm, P < 0.001). All except 1 patient as discussed above were free from significant AR, with mean peak and mean aortic gradients of 9.7 ± 5.6 mmHg and 5.4 ± 2.8 mmHg, respectively. None of the patients who underwent reoperation had significant regurgitation or stenosis of the reoperated aortic or pulmonary valves at follow-up. Eleven (9%) patients had moderate pulmonary regurgitation. The mean peak and mean pulmonary gradients were 20.0 ± 6.3 mmHg and 10.9 ± 6.1 mmHg, respectively.
DISCUSSION
The prevalence of significant AR in patients with BAV has been reported to vary between 11% and 32%, contributing to the high incidence of cardiovascular intervention rates of 22-57% in follow-up studies [11] [12] [13] . A recent systematic review of 11 502 
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patients with BAV found an incidence of aortic valve repair or replacement of 28% [14] . The majority of these patients underwent either an isolated AVR or concomitant aortic root replacement via a Bentall procedure when there is significant aortic root dilatation. The use of the Ross procedure as a surgical option has declined to <0.5% of AVRs [15] . This is likely a result of the allocation of Class IIb indication for the Ross procedure in the 2014 AHA/ACC Guidelines for management of valvular heart disease, stating it should only be considered in young patients where anticoagulation is contraindicated or undesirable [9] . The STS guidelines support a similarly unfavourable stance with the Ross procedure having a Class III indication, particularly highlighting its inadequacy in patients with BAV and AR [8] . However, it is our belief that with appropriate aortic root stabilising strategies, the Ross procedure is a viable option in this cohort. At latest follow-up (n = 128) NYHA Class 1, n (%) 128 (100) Moderate/severe LV systolic dysfunction, n (%) 0 Mean LVEDD (cm), mean ± SD 5.2 ± 0.5 Peak aortic gradient (mmHg), mean ± SD 9.7 ± 5.6 Mean aortic gradient (mmHg), mean ± SD 5.4 ± 2.8 Peak pulmonary gradient (mmHg), mean ± SD 20.0 ± 6.3 Mean pulmonary gradient (mmHg), mean ± SD 10.9 ± 6.1 LV: left ventricular; LVEDD: left ventricular end-diastolic diameter; NYHA: New York Heart Association; SD: standard deviation.
The ideal AVR option for young adults that provides freedom from reoperation, anticoagulation and valve-related morbidity remains elusive. Large studies have consistently demonstrated a survival disadvantage in patients who have undergone prosthetic AVRs compared to their age and gender matched counterparts, with the greatest disparity demonstrated in the younger group [16, 17] . This is due to the risk of stroke and bleeding, particularly in the setting of mechanical aortic valves [17] . However, there is great hesitation towards the Ross Procedure, due to its increased complexity and risk of perioperative complications and late reoperation. A landmark review of the STS database showed that operative mortality was twice as high after the Ross procedure as compared to propensity-matched patients who had undergone conventional AVR. They also faced an increased risk of early reoperation and renal failure. However, it is critical to note that more than half of the surgeons who performed the Ross procedure in this review were highly inexperienced, having completed only 5 or less surgeries [15] . Therefore, the results are not a representative comparison of the 2 strategies. Bioprosthetic AVR is gaining popularity in younger patients, with the prospect of having a 'valve-in-valve' transcatheter aortic valve replacement for management of late valve failure. However, the durability of bioprosthetic AVR is poor and has been associated with greater late mortality when compared to patients with mechanical AVRs [18] . The use of 'valve-in-valve' transcatheter aortic valve replacement has been demonstrated to be feasible in older patients; however, the mortality rates have been high and it has yet to be evaluated in younger patients.
The Ross procedure involves surgical intervention on 2 valves in order to address a single-valve pathology, hence accompanied by the risk of reoperation for both the autograft and homograft. Single-centre series have reported late autograft reoperation rates between 9% and 20% at a decade after the Ross procedure [19] [20] [21] . Patients with both BAV and AR are the most challenging patient group. This is a result of their propensity to develop progressive aortic root dilatation due to their underlying aortopathy. This was demonstrated in our results, with a larger preoperative sinotubular junction diameter remaining as the most important predictor of late autograft failure, despite our current surgical strategies. We have previously discussed the possible factors leading to late valve failure in an earlier publication [7] . These included uncorrected annular dilatation, the use of oversized supracoronary Dacron graft for ascending aortic replacement and presumed distortion of the autograft at implantation leading to cusp prolapse. As we routinely reduce all aortic annulus diameters to between 24 mm and 26 mm, current failures are likely due to the prolapse of the autograft leaflets. With a larger preoperative aortic root, more surgical manipulation is necessary, likely leading to more errors. Despite this, we believe that the use of an additional autologous support of the pulmonary autograft (inclusion technique) remains the key factor to our durable results.
The surgical experience in patients with BAV and AR is limited, with some studies reporting an increased rate of early autograft failure [22] . However, larger contemporary studies have demonstrated good mid-term outcomes with freedom from death and reoperation above 80% at 10 years [5, 23, 24] . As our unit had previously reported, extremely good long-term outcomes are achievable with surgical modifications to provide adequate support of the aortic root and prevent late dilatation [1] . The burden of late pulmonary homograft failure is minimal, with freedom from reintervention at over 90% 15 years later [25] . More importantly, late PVR has no impact on late survival. This is best demonstrated in patients undergoing late PVR after Tetralogy of Fallot repair [26, 27] , who are in fact a higher risk group because of their chronically impaired right ventricular function from birth. Redo pulmonary valve intervention was required in 3% of our cohort, all via surgical valve replacement. Our unit has commenced a programme for percutaneous PVR using the Melody TM Transcatheter Pulmonary Valve (Medtronic Inc., Minneapolis, MN, USA) in December 2016. None of these patients had this performed, but this is a possible strategy for all future patients requiring reintervention for their pulmonary valves.
Aortic valve repair is the alternative treatment option that has been gaining recent traction, with its potential offer of freedom from anticoagulation and valve-related complications. However, the long-term results in the BAV group are not superior to that achieved with the Ross procedure. Freedom from reoperation at 10 years is between 64% and 83%, with the predominant cause of reoperation being recurrent regurgitation secondary to cusp prolapse [28] [29] [30] . Moreover, aortic valve repair has a similar learning curve as with the Ross procedure. As such, long-term follow-up data beyond the 1st decade after repair is needed before aortic valve repair can be offered as a better treatment option. Our unit has also commenced an aortic valve repair programme, although mostly for tricuspid aortic valves. We currently reserve aortic valve repairs for BAVs to older patients with larger aortic roots, in whom a valve-sparing root replacement would be performed.
In our experience, we had a total reoperation rate of 11% over 25 years, of which only 7% was for AVR secondary to autograft failure. Valve failure usually presented early -within the first 5 years of follow-up. Our results were also confounded by the higher incidence of reoperation with the 'all-comers' approach before 1999. With the modification of our patient selection and surgical strategies in 1999, our reoperation rate has reduced to 6% (6/97). Therefore, despite the current guidelines, we believe that the Ross procedure should be considered a valid treatment option for patients with BAV and AR in centres with the necessary surgical expertise.
CONCLUSION
With a 20-year freedom from redo AVR and significant residual AR of 85%, we have demonstrated that very good results are attainable with the Ross procedure in adults with BAV presenting with pure AR. These results should serve as an important benchmark for comparison of long-term results, to determine whether there is a role for aortic valve repair in this cohort. Despite the recommendations of the current guidelines, we believe that the Ross procedure, when performed with adjunctive aortic root support in centres with surgical experience in these techniques, should be considered an acceptable treatment option in these patients.
